Anlotinib + Docetaxel
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Anlotinib + Docetaxel, covering 2018-08-31 to 2018-08-31. Get the full timeline:
Most recent: Clinical Trial Update: Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC [Phase 2]